Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PEA supplement shows promise for chronic back pain in new trial

NCT ID NCT06694337

Symptom relief Sponsor: Liaquat University of Medical & Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a dietary supplement called palmitoylethanolamide (PEA) can reduce nerve-related low back pain. 120 adults with chronic pain took either a low or high dose of PEA or a placebo for several weeks. Researchers measured pain intensity, disability, and quality of life to see if PEA helps more than a dummy pill.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Palmitoylethanolamide (PEA) supplement
What this could lead to
If it works, this could offer a natural supplement option to help ease nerve-related low back pain.
What could go wrong
This is a small, completed trial with no phase designation, so results may not be strong enough to recommend PEA widely. Supplements can have variable effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults, both Male or female aged ≥ 18 years and ≤ 80 years; * Diagnosed with neuropathic lower back pain for at least 3 months, as confirmed by clinical evaluation and DN4 (neuropathic pain 4 questions) screening questionnaire with score ≥4. * Pain intensity score ≥ 5 measured by NRS (Numerical Rating Scale) score, over the past week. * Willingness to adhere to study protocol, including visits, assessments, and self-reporting of symptoms. * Ability to provide informed consent and comply with study requirements. Exclusion Criteria: * Known intolerance or allergy to any component of the tested nutraceuticals * Presence of acute systemic disease * Presence of significant organic pathology * Current or past history of alcohol or drug abuse * History of malignancy within the past 5 years * Any significant concomitant disease or clinical condition that could compromise participant safety or interfere with study completion * Women of childbearing potential not using reliable contraceptive methods * Pregnancy or breastfeeding * Severe psychiatric disorders (e.g., major depression, schizophrenia) that could affect pain perception or adherence. * Inability to adhere to the study requirements due to lifestyle, transportation, or cognitive impairment. * Use of other cannabinoid-based therapies, investigational drugs, or concurrent participation in another clinical trial. * Dependence on opioid analgesics or recent opioid use that may interfere with pain assessment. * Current use of other supplements with potential anti-inflammatory or analgesic effects, including Omega-3 Fatty Acids, Turmeric/Curcumin, Glucosamine and Chondroitin, Boswellia Serrata, Methylsulfonylmethane.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Low back pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Low Back Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Low back pain

Contacts and locations

Locations

  • Lady Reading Hospital

    Peshawar, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.